Edition:
United States

Seattle Genetics Inc (SGEN.O)

SGEN.O on Nasdaq

55.02USD
24 Jul 2017
Change (% chg)

$0.63 (+1.16%)
Prev Close
$54.39
Open
$54.53
Day's High
$55.13
Day's Low
$54.13
Volume
878,550
Avg. Vol
954,641
52-wk High
$75.36
52-wk Low
$42.58

Latest Key Developments (Source: Significant Developments)

Seattle Genetics announces clinical collaboration to expand the therapeutic evaluation of sgn-liv1a
8:00am EDT 

July 24 (Reuters) - Seattle Genetics Inc ::Seattle Genetics announces clinical collaboration to expand the therapeutic evaluation of sgn-liv1a in triple negative breast cancer.Seattle Genetics Inc - ‍genentech will manage study operations for phase 1b/2 trial​.Seattle Genetics Inc - ‍seattle Genetics will retain global development and commercialization rights to sgn-liv1a​.  Full Article

Seattle Genetics reports 8.2 percent stake in Immunomedics as of June 29, 2017
Friday, 7 Jul 2017 05:20pm EDT 

July 7 (Reuters) - Seattle Genetics Inc : :Seattle genetics inc reports a 8.2 percent stake in immunomedics inc as of June 29, 2017 - sec filing.Seattle Genetics- acquired common stock, warrant in connection with development, license agreement with issuer to acquire strategic interest in Immunomedics.  Full Article

Takeda and Seattle Genetics announce positive results from phase 3 ECHELON-1 clinical trial
Monday, 26 Jun 2017 06:45am EDT 

June 26 (Reuters) - Seattle Genetics Inc :Takeda and Seattle Genetics announce positive results from phase 3 ECHELON-1 clinical trial evaluating Adcetris in frontline advanced hodgkin lymphoma.Says interim analysis of overall survival, key secondary endpoint, also trended in favor of Adcetris+AVD arm.Says safety profile of Adcetris+AVD in trial was consistent with that known for single-agent components of regimen.Says there was an increased incidence of febrile neutropenia and peripheral neuropathy in the Adcetris+AVD arm.Takeda and Seattle Genetics plan to submit trial results to regulatory authorities for approval in respective territories.phase 3 clinical trial met primary endpoint of statistically significant improvement in modified progression-free survival versus control arm.  Full Article

FDA notifies Seattle Genetics that IND for vadastuximab talirine placed on hold
Thursday, 22 Jun 2017 06:13am EDT 

June 22 (Reuters) - Seattle Genetics Inc ::Seattle Genetics Inc - fda notified co on June 21, IND for vadastuximab talirine has been placed on hold - SEC filing.Seattle Genetics Inc - FDA notified co that no clinical trials may resume under IND until FDA lifts clinical hold for vadastuximab talirine.  Full Article

Seattle Genetics submits supplemental biologics license application to fda for Adcetris
Tuesday, 20 Jun 2017 08:00am EDT 

June 20 (Reuters) - Seattle Genetics Inc ::Seattle Genetics submits supplemental biologics license application to FDA for Adcetris® (brentuximab vedotin) in cutaneous t-cell lymphoma.Seattle Genetics Inc - adcetris is currently not approved for treatment of ctcl.Seattle Genetics- trial achieved primary endpoint with adcetris treatment arm demonstrating highly statistically significant improvement for adcetris.Seattle Genetics- bla based on trial results from phase 3 alcanza,phase 2 investigator-sponsored studies in cutaneous t-cell lymphoma for adcetris.  Full Article

Seattle Genetics discontinues Phase 3 trial of vadastuximab talirine
Monday, 19 Jun 2017 06:45am EDT 

June 19 (Reuters) - Seattle Genetics Inc ::Seattle Genetics discontinues Phase 3 cascade trial of vadastuximab talirine (SGN-CD33A) in frontline acute myeloid leukemia.Seattle Genetics discontinues Phase 3 cascade trial of vadastuximab talirine (SGN-CD33A) in frontline acute myeloid leukemia.Seattle Genetics Inc - will closely review data and consult with FDA to determine future plans for vadastuximab talirine development program.Seattle Genetics - data indicated higher rate of deaths, including fatal infections in vadastuximab talirine-containing arm versus control arm of trial.Says ‍based on available data, safety concerns in this trial do not appear related to hepatotoxicity​.Seattle Genetics Inc - suspending patient enrollment and treatment in all of its vadastuximab talirine clinical trials.Seattle Genetics - on track to advance enfortumab vedotin into a pivotal trial in metastatic urothelial cancer in H2 2017 under collaboration with Astellas.  Full Article

Takeda, Seattle Genetics announce Lancet publication
Wednesday, 7 Jun 2017 08:00am EDT 

June 7 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>: :Takeda and Seattle Genetics announce Lancet publication of phase 3 alcanza clinical trial data of adcetris (brentuximab vedotin) for CD30-positive cutaneous t-cell lymphoma.Takeda - ‍takeda plans to begin to submit data from alcanza trial to regulatory agencies in its territories in 2017​.Takeda - ‍Seattle Genetics plans to submit these data as part of a supplemental biologics license application to FDA in mid-2017​.  Full Article

Seattle Genetics, Astellas announce updated enfortumab vedotin phase 1 data in metastatic urothelial cancer ​
Monday, 5 Jun 2017 10:45am EDT 

June 5 (Reuters) - Astellas Pharma Inc <4503.T>::Trial evaluating enfortumab vedotin in combination with CPIs is also planned for later in the year​.Cos this year plan to initiate registrational monotherapy phase 2 trial for locally advanced/ MUC patients previously treated with CPI therapy.  Full Article

Bristol-Myers Squibb and Seattle Genetics expand collaboration to evaluate combination of opdivo and adcetris
Friday, 2 Jun 2017 06:00am EDT 

June 2 (Reuters) - Bristol-myers Squibb Co :Bristol-Myers Squibb and Seattle Genetics expand clinical collaboration to evaluate combination of opdivo (nivolumab) and adcetris® (brentuximab vedotin) in pivotal phase 3 clinical trial in relapsed hodgkin lymphoma.Bristol-Myers Squibb Co - ‍pivotal phase 3 trial planned for mid-2017​.Bristol-Myers - phase 3 trial to evaluate adcetris alone or with opdivo in relapsed/refractory or transplant-ineligible advanced classical hodgkin lymphoma.Bristol-Myers Squibb- in addition to planned trial, adcetris, opdivo being evaluated as combination therapy in multiple ongoing phase 1/2 clinical trials.Bristol-Myers Squibb Co -adcetris, opdivo combination being evaluated for older hl patients,relapsed/refractory classical hl for children, adolescents.  Full Article

Immunomedics announces private placement offering
Friday, 5 May 2017 08:46am EDT 

May 5 (Reuters) - Immunomedics Inc : :Immunomedics delivers business updates, announces private placement offering and outlines strategic steps to drive stockholder value.Immunomedics Inc - cfo michael garone to be named interim ceo once settlement agreement is finalized.Immunomedics Inc - board in process of considering candidates for permanent CEO.Immunomedics - has raised $125 million in gross proceeds in private placement of its series A-1 convertible preferred stock with institutional investors.Immunomedics Inc - now targeting submission of a BLA for Immu-132 for approval in MTNBC between late Q4 2017 and q1 2018.Immunomedics - to proceed with final selection of cro to launch confirmatory phase 3 study, expect first patient enrolled in late Q3 2017 for immu-132.Immunomedics Inc - Cynthia L. Sullivan will be stepping down from all director and officer positions with company.Immunomedics Inc - David M. Goldenberg, founder of company, is stepping down from all officer positions with company.Immunomedics Inc - Goldenberg will continue to serve as a director on Immunomedics' board.Immunomedics Inc - entered into a binding term sheet with Goldenberg, Sullivan, Markison and Venbio.Immunomedics Inc - Immunomedics expects to have sufficient operating funds through Q3 of 2018.Immunomedics Inc - regarding venbio action, individual defendants Goldenberg, Sullivan And Markison will be released from all claims made by Venbio.  Full Article

BRIEF-Seattle Genetics announces clinical collaboration to expand the therapeutic evaluation of sgn-liv1a

* Seattle Genetics announces clinical collaboration to expand the therapeutic evaluation of sgn-liv1a in triple negative breast cancer